+91 9891296838 / 9811747774
Trastuzumab emtansine also known as ado-trastuzumab emtansine and sold under the trade name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1. Trastuzumab alone stops growth of cancer cells by binding to the HER2 receptor, whereas trastuzumab emtansine undergoes receptor-mediated internalization into cells, is catabolized in lysosomes where DM1-containing catabolites are released and subsequently bind tubulin to cause mitotic arrest and cell death.
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of Ado-trastuzumab emtansine brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the ALUNBRIG (brigatinib) tablets cost price in India.
The order for Ado-trastuzumab emtansine will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
KADCYLA™ (ado-trastuzumab emtansine) for injection, for intravenous use. Initial U.S. Approval: 2013
Generic Name: brigatinib
Lyophilized powder in single-use vials containing 100 mg per vial or 160 mg per vial.
60/4 1st Floor, T&T Building, Indian Oil Complex,
Yusuf Sarai, New Delhi, Delhi 110016
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand KADCYLA (ado-trastuzumab emtansine) on prescription and Import License in Patient's Name only.
For overseas patients, Ado-trastuzumab emtansine can be made available in Send your enquiry to find KADCYLA (ado-trastuzumab emtansine) in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For KADCYLA (ado-trastuzumab emtansine) Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
Genentech’s Kadcyla Wins Second FDA Approval for HER2-Positive Breast Cancer For More Details
Roche’s Kadcyla gets FDA nod for adjuvant treatment of HER2+ early breast cancer For More Details